Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial - The Lancet
4.6
$ 11.00
In stock
(397)
Product Description
The pipeline of new molecules and regimens against drug-resistant
Treatment of isoniazid-resistant tuberculosis with first-line
Mortality from drug-resistant tuberculosis in high-burden
Summary of Failure or Relapse (FoR) event in MITT analysis
The epidemiology, pathogenesis, transmission, diagnosis, and
Economic evaluation of shortened, bedaquiline-containing treatment
Jornal Brasileiro de Pneumologia - Shortened tuberculosis
Intermittent regimens for tuberculosis treatment: Back to the
Nomogram for individualized prediction of incident multidrug
Pretomanid for tuberculosis treatment: an update for clinical
/cdn.vox-cdn.com/uploads/chorus_asset/file/23428465/1240313932.jpg)
